The cryptic fusion NUP214-ABL1 resulting in epigenetic amplification of ABL1 has been described in 5–10% of T-ALL cases [51,52] rendering them sensitive to inhibition by tyrosine kinase inhibitors Imatinib, Nilotinib, and Dasatinib [53]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.